Table 3.
Emerging targets with clinical significance in PC
| Molecular target | Class | Trial | Disease setting | Agent | Experimental treatment | Study phase | Estimated completion |
|---|---|---|---|---|---|---|---|
| Hormonal Therapy | Second-generation ADT | NCT03098836 | mCRPC | Apalutamide | Apalutamide + abiraterone | Phase II | June 2021 |
| NCT02106507 | mCRPC | Apalutamide | Apalutamide +everolimus | Phase I | April 2020 | ||
|
(TITAN) |
mCSPC | Apalutamide | Apalutamide + ADT | Phase III | July 2022 | ||
| New-generation ADT |
(ARAMIS) |
nmCRPC | Darolutamide | Darolutamide | Phase III | June 2020 | |
| AR inhibitor | NCT02445976 | CRPC Progressing on Enzalutamide or Abiraterone | Seviteronel | Seviteronel | Phase II | January 2019* | |
| NCT02012920 | CRPC | Seviteronel | Seviteronel | Phase II | January 2019* | ||
| Tumor Vaccine | Dendritic Cells |
(VIABLE) |
mCRPC | DCVAC | DCVAC | Phase III | June 2020 |
| PD-L1 and CTLA-4 | CPI |
(KEYNOTE-365) |
mCRPC |
Pembrolizumab + olaparib or Pembrolizumab + docetaxel + prednisone or Pembrolizumab + enzalutamide |
Phase I | May 2022 | |
|
(CheckMate-650) |
mCRPC | Nivolumab + Ipilimumab | Phase II | March 2022 | |||
| PD-L1 |
(KEYNOTE-199) |
mCRPC | Pembrolizumab |
Pembrolizumab monotherapy or Pembrolizumab + enzalutamide |
Phase II | December 2020 | |
| PARP Inhibitor | DNA Repair Inhibition |
(KEYLYNK-010) |
mCRPC | Pembrolizumab + olaparib | Pembrolizumab + olaparib | Phase III | September 2022 |
| NCT03732820 | Previously-untreated mCRPC | Abiraterone + olaparib | Abiraterone | Phase III | August 2022 | ||
| Radioisotope | NCT03737370 | mCRPC | Radium-223 | Radium-223 + docetaxel | Phase I | October 2021 | |
|
ACTRN12615000912583** (LuPSMA Trial) |
mCRPC | 177Lutetium | Phase I/II | N/A | |||
All trial information obtained through publicly accessible clinicaltrials.gov
*Results pending
**Trial filed in Australia New Zealand Clinical trials registry, http://www.anzctr.org.au